全文获取类型
收费全文 | 1527912篇 |
免费 | 115818篇 |
国内免费 | 17542篇 |
学科分类
医药卫生 | 1661272篇 |
出版年
2021年 | 16313篇 |
2020年 | 13383篇 |
2019年 | 15295篇 |
2018年 | 19461篇 |
2017年 | 16411篇 |
2016年 | 16962篇 |
2015年 | 21817篇 |
2014年 | 28823篇 |
2013年 | 35524篇 |
2012年 | 48414篇 |
2011年 | 52187篇 |
2010年 | 30889篇 |
2009年 | 28109篇 |
2008年 | 44204篇 |
2007年 | 47235篇 |
2006年 | 47999篇 |
2005年 | 46914篇 |
2004年 | 41709篇 |
2003年 | 40299篇 |
2002年 | 38701篇 |
2001年 | 67531篇 |
2000年 | 69686篇 |
1999年 | 60041篇 |
1998年 | 17076篇 |
1997年 | 15862篇 |
1996年 | 14763篇 |
1995年 | 14653篇 |
1994年 | 13469篇 |
1992年 | 44330篇 |
1991年 | 42643篇 |
1990年 | 41607篇 |
1989年 | 40410篇 |
1988年 | 37744篇 |
1987年 | 37043篇 |
1986年 | 35439篇 |
1985年 | 33522篇 |
1984年 | 25039篇 |
1983年 | 21162篇 |
1979年 | 23961篇 |
1978年 | 17049篇 |
1977年 | 14797篇 |
1976年 | 13346篇 |
1975年 | 15249篇 |
1974年 | 18080篇 |
1973年 | 17560篇 |
1972年 | 16823篇 |
1971年 | 15717篇 |
1970年 | 14891篇 |
1969年 | 14338篇 |
1968年 | 13451篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Yue Wentao Zhang Enjie Liu Ruixia Zhang Yue Wang Chengrong Gao Shen Su Shaofei Gao Xiao Wu Qingqing Yang Xiaokui Papageorghiou Aris T. Yin Chenghong 《European journal of epidemiology》2022,37(3):295-304
European Journal of Epidemiology - The China birth cohort study (CBCS) is a prospective longitudinal, mega-cohort study and the first national-based birth cohort study, aiming to establish a birth... 相似文献
52.
目的 克隆菊花脑芳樟醇合酶基因CnTPS1的全长编码序列,利用原核系统表达融合蛋白,为进一步研究该基因在菊花脑萜类合成中的功能提供理论依据。方法 以菊花脑基因组数据为基础,设计特异性引物,PCR扩增CnTPS1的全长编码序列,利用生物信息学分析软件分析序列特征。利用qRT-PCR技术分析CnTPS1基因在不同组织中的基因表达量。构建原核表达载体,体外诱导目的蛋白表达。结果 CnTPS1编码序列全长1749bp,编码582个氨基酸;基因表达模式分析表明该基因在茎和管状花中表达量较高;原核表达系统能诱导出67.58kDa大小的蛋白。结论 首次从菊花脑中克隆得到一个芳樟醇合酶基因CnTPS1,运用生物信息学方法对其编码蛋白的理化性质、结构特征等进行了分析预测,分析了该基因的组织表达模式,并在原核表达系统中成功诱导表达出目标蛋白,这些结果将为菊花脑萜类合酶基因的功能以及萜类物质生物合成途径的解析提供理论依据。 相似文献
53.
54.
55.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
56.
Tianshu Liu Yuxian Bai Xiaoyan Lin Wei Li Jufeng Wang Xiaochun Zhang Hongming Pan Chunmei Bai Li Bai Ying Cheng Jingdong Zhang Haijun Zhong Yi Ba Wenwei Hu Ruihua Xu Weijian Guo Shukui Qin Nong Yang Jianwei Lu Kohei Shitara Ming Lei Mingshun Li Nicole Bao Tian Chen Lin Shen 《International journal of cancer. Journal international du cancer》2023,152(4):749-760
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC. 相似文献
57.
Michala G. Rolver Lya K. K. Holland Muthulakshmi Ponniah Nanditha S. Prasad Jiayi Yao Julie Schnipper Signe Kramer Line Elingaard-Larsen Elena Pedraz-Cuesta Bin Liu Luis A. Pardo Kenji Maeda Albin Sandelin Stine Falsig Pedersen 《International journal of cancer. Journal international du cancer》2023,152(8):1668-1684
The mechanisms linking tumor microenvironment acidosis to disease progression are not understood. Here, we used mammary, pancreatic, and colon cancer cells to show that adaptation to growth at an extracellular pH (pHe) mimicking acidic tumor niches is associated with upregulated net acid extrusion capacity and elevated intracellular pH at physiological pHe, but not at acidic pHe. Using metabolic profiling, shotgun lipidomics, imaging and biochemical analyses, we show that the acid adaptation-induced phenotype is characterized by a shift toward oxidative metabolism, increased lipid droplet-, triacylglycerol-, peroxisome content and mitochondrial hyperfusion. Peroxisome proliferator-activated receptor-α (PPARA, PPARα) expression and activity are upregulated, at least in part by increased fatty acid uptake. PPARα upregulates genes driving increased mitochondrial and peroxisomal mass and β-oxidation capacity, including mitochondrial lipid import proteins CPT1A, CPT2 and SLC25A20, electron transport chain components, peroxisomal proteins PEX11A and ACOX1, and thioredoxin-interacting protein (TXNIP), a negative regulator of glycolysis. This endows acid-adapted cancer cells with increased capacity for utilizing fatty acids for metabolic needs, while limiting glycolysis. As a consequence, the acid-adapted cells exhibit increased sensitivity to PPARα inhibition. We conclude that PPARα is a key upstream regulator of metabolic changes favoring cancer cell survival in acidic tumor niches. 相似文献
58.
Eileen M. Dryden PhD Meaghan A. Kennedy MD MPH Jennifer Conti MPH Jacqueline H. Boudreau MPH Chitra P. Anwar MA Kathryn Nearing PhD MA Camilla B. Pimentel PhD MPH William W. Hung MD MPH Lauren R. Moo MD 《Health services research》2023,58(Z1):26-35
Objective
Explore the perceived benefits of a Veterans Health Administration (VHA) geriatric specialty telemedicine service (GRECC Connect) among rural, older patients and caregivers to contribute to an assessment of its quality and value.Data Sources
In Spring 2021, we interviewed a geographically diverse sample of rural, older patients and their caregivers who participated in GRECC Connect telemedicine visits.Study Design
A cross-sectional qualitative study focused on patient and caregiver experiences with telemedicine, including perceived benefits and challenges.Data Collection
We conducted 30 semi-structured qualitative interviews with rural, older (≥65) patients enrolled in the VHA and their caregivers via videoconference or phone. Interviews were recorded, transcribed, and analyzed using a rapid qualitative analysis approach.Principal Findings
Participants described geriatric specialty telemedicine visits focused on cognitive assessments, tailored physical therapy, medication management, education on disease progression, support for managing multiple comorbidities, and suggestions to improve physical functioning. Participants reported that, in addition to prescribing medications and ordering tests, clinicians expedited referrals, coordinated care, and listened to and validated both patient and caregiver concerns. Perceived benefits included improved patient health; increased patient and caregiver understanding and confidence around symptom management; and greater feelings of empowerment, hopefulness, and support. Challenges included difficulty accessing some recommended programs and services, uncertainty related to instructions or follow-up, and not receiving as much information or treatment as desired. The content of visits was well aligned with the domains of the Age-Friendly Health Systems and Geriatric 5Ms frameworks (Medication, Mentation, Mobility, what Matters most, and Multi-complexity).Conclusions
Alignment of patient and caregiver experiences with widely-used models of comprehensive geriatric care indicates that high-quality geriatric care can be provided through virtual modalities. Additional work is needed to develop strategies to address challenges and optimize and expand access to geriatric specialty telemedicine. 相似文献59.
60.